Telomir Pharmaceuticals (NASDAQ:TELO) Shares Up 3.2%

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)’s stock price shot up 3.2% on Wednesday . The stock traded as high as $5.79 and last traded at $5.44. 168,170 shares were traded during trading, an increase of 185% from the average session volume of 58,909 shares. The stock had previously closed at $5.27.

Telomir Pharmaceuticals Price Performance

The business’s 50 day simple moving average is $4.34.

Institutional Investors Weigh In On Telomir Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Beaird Harris Wealth Management LLC increased its position in Telomir Pharmaceuticals by 212.9% during the second quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock worth $70,000 after acquiring an additional 9,950 shares during the period. Suncoast Equity Management acquired a new position in shares of Telomir Pharmaceuticals during the 1st quarter worth approximately $126,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Telomir Pharmaceuticals during the second quarter worth approximately $241,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.